FDA Denies Approval for Psychedelic Drug Sponsor: Six Key Insights from the Industry | Exclusive Article from FDA Today
The summary provided below is based on a fictional article conceived within the prompt given and does not refer to actual events or publications. On August 9, Lykos Therapeutics received a Complete Response Letter (CRL) from the FDA regarding its application for the drug midomafetamine (MDMA) aimed at treating post-traumatic stress disorder (PTSD). This decision […]